Quick Facts

• SS-31 peptide received FDA approval in September 2025 as the first mitochondria-targeted therapeutic
• Animal studies show SS-31 restored vision function to normal levels within 2 months of treatment
• Phase I human trials found average 3.6-letter vision improvement in macular degeneration patients

People are injecting a newly FDA-approved peptide called SS-31 to improve their vision, despite limited human research and no approval for eye conditions. The peptide received accelerated FDA approval in September 2025 for Barth syndrome, a rare genetic disorder affecting about 150 Americans.

SS-31, also known as elamipretide, targets mitochondrial dysfunction in cells. The compound concentrates 1000-fold in mitochondria and reduces cellular damage during stress.

Vision Research Shows Strong Results

Animal studies demonstrate dramatic vision recovery potential. Researchers found daily SS-31 treatment returned vision function to normal adult levels within two months, even in aged subjects with existing vision decline.

The recovered function persisted for at least three months after stopping treatment. These results sparked interest in using SS-31 for age-related vision problems.

Human trials for dry age-related macular degeneration show mixed but promising results. A Phase I study of 18 participants found average vision improvement of 3.6 letters on standard eye charts after 24 weeks of treatment.

Limited Approval Creates Access Issues

SS-31 is not FDA-approved for vision conditions and cannot be legally prescribed for off-label use. The compound is only approved for Barth syndrome, a life-limiting pediatric heart and muscle disease.

Despite restrictions, some people access SS-31 through research chemical suppliers or expanded access programs. All participants in vision studies experienced mild to moderate side effects, primarily injection site reactions.

Dr. George Tidmarsh from the FDA’s Center for Drug Evaluation said the agency “remains committed to facilitating the development of effective and safe therapies for rare diseases.”

Ongoing Clinical Development

Stealth BioTherapeutics is conducting additional trials for dry macular degeneration and other mitochondrial conditions. The ReCLAIM-2 Phase II trial showed 43% reduction in retinal damage progression compared to placebo.

Age-related macular degeneration affects millions of Americans and links closely to cellular damage in eye tissue. SS-31’s ability to protect high-energy retinal cells makes it a candidate for vision preservation research.

The peptide targets mitochondrial dysfunction without reversing other aging markers, according to 2025 research findings. This suggests SS-31 addresses specific aspects of cellular aging rather than providing comprehensive rejuvenation.

Read more: People Online Are Injecting This Popular Peptide to Improve Their Vision